[go: up one dir, main page]

MX2021010759A - Regimen de dosificacion para un agonista de los receptores de s1p. - Google Patents

Regimen de dosificacion para un agonista de los receptores de s1p.

Info

Publication number
MX2021010759A
MX2021010759A MX2021010759A MX2021010759A MX2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A
Authority
MX
Mexico
Prior art keywords
dosage regimen
receptor agonist
dosage
daily dosage
regimen
Prior art date
Application number
MX2021010759A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Michael Looby
David Olivier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021010759A publication Critical patent/MX2021010759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
MX2021010759A 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p. MX2021010759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
MX2021010759A true MX2021010759A (es) 2022-07-19

Family

ID=41667217

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018006099A MX385959B (es) 2008-12-22 2009-12-21 Régimen de dosificación para un agonista de los receptores de s1p.
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.
MX2021010759A MX2021010759A (es) 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018006099A MX385959B (es) 2008-12-22 2009-12-21 Régimen de dosificación para un agonista de los receptores de s1p.
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.

Country Status (43)

Country Link
US (12) US20100160259A1 (es)
EP (7) EP3453387B1 (es)
JP (7) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (4) CY1116990T1 (es)
DK (4) DK3453387T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (4) ES2552823T3 (es)
FI (2) FI4098256T3 (es)
FR (2) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (4) HRP20250568T1 (es)
HU (6) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (5) LT3409274T (es)
LU (1) LUC00183I2 (es)
MA (1) MA32981B1 (es)
ME (2) ME03802B (es)
MX (3) MX385959B (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (4) PL4098256T3 (es)
PT (4) PT3453387T (es)
RS (3) RS66784B9 (es)
SG (1) SG171404A1 (es)
SI (4) SI3453387T1 (es)
SM (2) SMT202000441T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
ES2552823T3 (es) 2008-12-22 2015-12-02 Novartis Ag Régimen de dosificación para fingolimod para el tratamiento de la esclerosis múltiple
BR112012006957A2 (pt) 2009-09-29 2016-06-14 Novartis Ag regime de dosagem de um modulador de receptor de s1p
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
MA34897B1 (fr) 2011-01-07 2014-02-01 Novartis Ag Formulations d'immunosupresseurs
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) * 2011-10-11 2013-06-01 Novartis Ag 投藥療程
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
RU2020107732A (ru) * 2014-04-10 2020-03-30 Новартис Аг Схема дозирования модулятора s1p с немедленным высвобождением
PL3256125T3 (pl) 2014-12-11 2022-05-09 Actelion Pharmaceuticals Ltd Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
CA3169569A1 (en) * 2020-02-28 2021-09-02 Damian Grobelny S1p receptor modulators
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2495690T3 (es) * 2004-11-29 2014-09-17 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006085316A2 (en) * 2005-02-10 2006-08-17 G.I. View Ltd. Advancement techniques for gastrointestinal tool with guiding element
EP2465492B1 (en) * 2007-10-12 2015-07-01 Novartis AG Compositions comprising sphingosine I phosphate (sip) receptor modulators
DK2278960T4 (da) * 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
AR074825A1 (es) 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion de un agonista de los receptores de s1p, metodo de tratamiento y kit
ES2552823T3 (es) 2008-12-22 2015-12-02 Novartis Ag Régimen de dosificación para fingolimod para el tratamiento de la esclerosis múltiple

Also Published As

Publication number Publication date
HUE026869T2 (en) 2016-08-29
JP2012513401A (ja) 2012-06-14
SMT202000054T1 (it) 2020-03-13
JP2017141238A (ja) 2017-08-17
CL2013001558A1 (es) 2013-10-25
LT3453387T (lt) 2020-08-25
TN2011000272A1 (en) 2012-12-17
FR20C1060I1 (fr) 2020-12-25
AR074826A1 (es) 2011-02-16
US20250262171A1 (en) 2025-08-21
DK3409274T3 (da) 2019-12-16
DK2379067T3 (en) 2015-12-07
AU2009330176B2 (en) 2014-03-06
ZA201205942B (en) 2013-03-27
FIC20253002I1 (fi) 2025-05-23
AU2009330176A1 (en) 2011-07-07
CY1123255T1 (el) 2021-10-29
EP4098256B1 (en) 2025-02-26
JP2024129030A (ja) 2024-09-26
ME03802B (me) 2021-04-20
HUE052048T2 (hu) 2021-04-28
HRP20250568T1 (hr) 2025-07-04
SI3409274T1 (sl) 2020-03-31
PT3453387T (pt) 2020-08-11
LTPA2020005I1 (lt) 2020-12-10
AU2009330176C9 (en) 2017-01-05
HUE048717T2 (hu) 2020-08-28
IL213170A0 (en) 2011-07-31
HUE048717T4 (hu) 2022-02-28
HN2011001759A (es) 2013-11-26
EP3120844A1 (en) 2017-01-25
ECSP11011222A (es) 2011-08-31
RS66784B1 (sr) 2025-06-30
KR20110096175A (ko) 2011-08-29
ES3017254T3 (en) 2025-05-12
EP2379067A1 (en) 2011-10-26
MX385959B (es) 2025-03-18
US20110257133A1 (en) 2011-10-20
US20190091180A1 (en) 2019-03-28
MA32981B1 (fr) 2012-01-02
CY2020036I1 (el) 2021-03-12
DK3453387T3 (da) 2020-08-10
DK4098256T3 (da) 2025-04-22
HRP20192175T1 (hr) 2020-03-20
EP3409274A1 (en) 2018-12-05
DK4098256T5 (da) 2025-07-21
RS60666B1 (sr) 2020-09-30
SG171404A1 (en) 2011-07-28
US20180289638A1 (en) 2018-10-11
WO2010075239A1 (en) 2010-07-01
PL3453387T3 (pl) 2020-11-02
EA201100978A1 (ru) 2012-01-30
US20160263061A1 (en) 2016-09-15
US20220142949A1 (en) 2022-05-12
SI3453387T1 (sl) 2020-10-30
HUE071189T2 (hu) 2025-08-28
US20100160259A1 (en) 2010-06-24
EP3453387B1 (en) 2020-06-03
LTPA2025520I1 (es) 2025-06-25
PL3409274T3 (pl) 2020-06-01
US20170189353A1 (en) 2017-07-06
US20140148415A1 (en) 2014-05-29
HRP20201167T1 (hr) 2020-12-11
UY32352A (es) 2010-07-30
PL2379067T3 (pl) 2016-02-29
LT3409274T (lt) 2020-02-10
EP4098256B9 (en) 2025-06-18
PT4098256T (pt) 2025-04-10
EP3409274B1 (en) 2019-11-20
NZ593065A (en) 2012-11-30
EP2907511A1 (en) 2015-08-19
SI4098256T1 (sl) 2025-06-30
EP3453387A1 (en) 2019-03-13
HUS2500026I1 (hu) 2025-07-28
JP2016135752A (ja) 2016-07-28
EP4098256A1 (en) 2022-12-07
IL274756A (en) 2020-07-30
JP2014144970A (ja) 2014-08-14
US20140066657A1 (en) 2014-03-06
AU2009330176C1 (en) 2016-12-08
CN102264359A (zh) 2011-11-30
HUS2000046I1 (hu) 2020-12-28
EP2379067B1 (en) 2015-09-02
US20160081949A1 (en) 2016-03-24
CA2747802A1 (en) 2010-07-01
SI2379067T1 (sl) 2016-01-29
LT4098256T (lt) 2025-06-10
CA2747802C (en) 2021-02-09
CY1122812T1 (el) 2021-05-05
JP7329965B2 (ja) 2023-08-21
CO6390117A2 (es) 2012-02-29
CL2011001529A1 (es) 2012-02-24
ME03594B (me) 2020-07-20
SMT202000441T1 (it) 2020-09-10
PT2379067E (pt) 2015-12-23
MX2011006623A (es) 2011-07-12
RS66784B9 (sr) 2025-08-29
HRP20151190T1 (hr) 2016-01-01
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
TW201028143A (en) 2010-08-01
ES2810823T3 (es) 2021-03-09
LUC00183I2 (es) 2024-07-01
KR101347919B1 (ko) 2014-01-07
ZA201103863B (en) 2012-10-31
FR25C1012I1 (fr) 2025-06-13
FI4098256T3 (fi) 2025-03-31
EP3677260A1 (en) 2020-07-08
PE20120337A1 (es) 2012-04-24
NO2020038I1 (no) 2020-11-18
JP2022103194A (ja) 2022-07-07
CR20110274A (es) 2011-07-19
PT3409274T (pt) 2019-12-17
US20200330407A1 (en) 2020-10-22
JP2019167360A (ja) 2019-10-03
ES2552823T3 (es) 2015-12-02
CY2020036I2 (el) 2021-06-25
CU20110136A7 (es) 2012-01-31
PL4098256T3 (pl) 2025-06-09
RS59857B1 (sr) 2020-02-28
CY1116990T1 (el) 2017-04-05
ES2760607T3 (es) 2020-05-14

Similar Documents

Publication Publication Date Title
TN2011000272A1 (en) Dosage regimen for a s1p agonist
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2012000704A (es) Agonistas de gpr119.
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
PH12012502162A1 (en) Combination therapy
MX2012011631A (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
GB0812642D0 (en) Compounds
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
UA106219C2 (ru) Модуляторы толл-подобных рецепторов
CL2010000497A1 (es) Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k
UA56535U (ru) Способ лечения функциональной кисты после резекции яичника